Tate & Lyle (TATYY)
OTHER OTC:TATYY
Top Page
Tate & Lyle
(OTC:TATYY)
Select Model
Select Model
Rating:63Neutral
Price Target:
$19.00
▼(-3.46% Downside)
Action:ReiteratedDate:12/07/25
Tate & Lyle's overall stock score reflects stable financial performance with challenges in profitability and cash flow. Technical analysis indicates a bearish trend, and the high P/E ratio suggests overvaluation. Despite revenue and EBITDA declines, the earnings call highlighted potential growth opportunities, balancing the overall outlook.
Positive Factors
M&A-driven cross-selling
The CP Kelco combination has materially expanded the addressable portfolio and the cross-selling pipeline, creating a durable source of incremental revenue. Doubling pipeline value implies stronger customer engagement, higher lifetime customer value, and multi-year upside from integrated sales and shared routes to market.
Negative Factors
Near-term revenue and EBITDA declines
Management guidance for falling revenue and EBITDA reflects persistent category softness and weaker demand that can compress operating leverage. Over the next several quarters this reduces earnings power, limits reinvestment capacity and can slow recovery even as strategic initiatives progress.
Read all positive and negative factors
Positive Factors
Negative Factors
M&A-driven cross-selling
The CP Kelco combination has materially expanded the addressable portfolio and the cross-selling pipeline, creating a durable source of incremental revenue. Doubling pipeline value implies stronger customer engagement, higher lifetime customer value, and multi-year upside from integrated sales and shared routes to market.
Read all positive factors
Tate & Lyle (TATYY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.06B
Dividend Yield5.06%
Average Volume (3M)2.30K
Price to Earnings (P/E)9.1
Beta (1Y)0.47
Revenue Growth30.86%
EPS Growth-79.99%
CountryUS
Employees3,318
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)1.12
Shares Outstanding111,361,694
10 Day Avg. Volume956
30 Day Avg. Volume2,299
Financial Highlights & Ratios
PEG Ratio-0.62
Price to Book (P/B)4.06
Price to Sales (P/S)3.72
P/FCF Ratio150.07
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue1.42
Enterprise Value/Gross Profit-47.19
Enterprise Value/Ebitda10.48
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.29
Revenue Forecast (FY)$2.74B
Tate & Lyle Business Overview & Revenue Model
Company Description
Tate & Lyle is a global provider of food and beverage ingredients, focused on creating sustainable and innovative solutions for the food industry. The company operates primarily in two segments: Food & Beverage Solutions and Sucralose. Its core pr...
How the Company Makes Money
Tate & Lyle makes money primarily by selling specialty ingredient products and solutions to food and beverage manufacturers and, to a lesser extent, foodservice-related customers. Revenue is generated through (1) product sales of functional ingred...
Tate & Lyle Earnings Call Summary
Earnings Call Date:Nov 06, 2025
(Q2-2026)
| % Change Since: |
Next Earnings Date:May 21, 2026
Earnings Call Sentiment Neutral
The earnings call reflects a challenging market environment with revenue and EBITDA declines, impacted by tariffs and category softness. However, there are notable successes such as the doubling of the cross-selling pipeline value and strong demand for sucralose, indicating potential for future growth.Positive Updates
CP Kelco Combination Success
The value of the cross-selling pipeline has more than doubled in the last 2 months, demonstrating strong customer engagement with the combined portfolio and expertise in mouthfeel.
Negative Updates
Revenue and EBITDA Decline
Group revenue is expected to be 3% to 4% lower, with EBITDA in the first half expected to decline by high single-digit percent.
Read all updates
Q2-2026 Updates
Positive
Negative
CP Kelco Combination Success
The value of the cross-selling pipeline has more than doubled in the last 2 months, demonstrating strong customer engagement with the combined portfolio and expertise in mouthfeel.
Read all positive updates
Company Guidance
In the recent conference call, Tate & Lyle provided guidance for the first half of fiscal year 2026, indicating that Group revenue is expected to decline by 3% to 4% in constant currency, compared to pro forma comparatives, due to a challenging market environment. The company noted a slowdown in demand, particularly in the Americas, where revenue is expected to be slightly lower due to softer consumer demand in North America. In Europe, Middle East, and Africa, revenue is projected to be mid-single-digit lower, and in Asia Pacific, it is expected to be broadly in line despite tariffs. EBITDA for the first half is anticipated to be high single-digit percent lower, reflecting top-line softness and ongoing growth investments. For the full year ending March 31, 2026, revenue and EBITDA are expected to decline by low single-digit percent. Despite these challenges, the company is optimistic about future growth driven by the CP Kelco combination, with the cross-selling pipeline more than doubling in value in the last two months.Tate & Lyle Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
68
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.77B | 1.74B | 1.65B | 1.75B | 1.38B | 1.21B |
| Gross Profit | -53.00M | 706.00M | 851.00M | 733.00M | 514.00M | 481.00M |
| EBITDA | 238.68M | 254.00M | 345.00M | 279.00M | 168.00M | 292.00M |
| Net Income | 33.87M | 143.00M | 188.00M | 190.00M | 236.00M | 253.00M |
Balance Sheet | ||||||
| Total Assets | 3.60B | 3.73B | 2.28B | 2.51B | 3.25B | 2.97B |
| Cash, Cash Equivalents and Short-Term Investments | 325.24M | 334.00M | 437.00M | 475.00M | 112.00M | 371.00M |
| Total Debt | 1.29B | 1.31B | 590.00M | 713.00M | 679.00M | 786.00M |
| Total Liabilities | 2.06B | 2.14B | 1.04B | 1.32B | 1.63B | 1.51B |
| Stockholders Equity | 1.55B | 1.59B | 1.24B | 1.19B | 1.62B | 1.45B |
Cash Flow | ||||||
| Free Cash Flow | 69.83M | 43.00M | 98.00M | -12.00M | -45.00M | 217.00M |
| Operating Cash Flow | 119.72M | 164.00M | 208.00M | 66.00M | 103.00M | 369.00M |
| Investing Cash Flow | -53.00M | -630.00M | -20.00M | 835.00M | -113.00M | -205.00M |
| Financing Cash Flow | -69.00M | 367.00M | -215.00M | -598.00M | -247.00M | -29.00M |
Tate & Lyle Technical Analysis
Negative
19.68
Price Trends
19.96
Negative
19.91
Negative
22.70
Negative
Market Momentum
-0.32
Negative
45.07
Neutral
73.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TATYY, the sentiment is Negative. The current price of 19.68 is above the 20-day moving average (MA) of 18.52, below the 50-day MA of 19.96, and below the 200-day MA of 22.70, indicating a neutral trend. The MACD of -0.32 indicates Negative momentum. The RSI at 45.07 is Neutral, neither overbought nor oversold. The STOCH value of 73.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TATYY.
Tate & Lyle Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $8.46B | 8.73 | 30.72% | ― | 1.81% | 24.67% | |
69 Neutral | $7.13B | 10.63 | 17.25% | 2.86% | -3.83% | -2.04% | |
63 Neutral | $2.06B | 9.08 | 2.17% | 5.06% | 30.86% | -79.99% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
54 Neutral | $6.23B | 14.14 | 13.98% | 5.64% | 2.71% | 4.90% | |
54 Neutral | $7.41B | 11.30 | -0.51% | 7.87% | -5.82% | -119.70% | |
52 Neutral | $5.60B | 30.39 | 16.90% | 3.37% | 2.35% | 9.61% |
* Consumer Defensive Sector Average
TATYY
Tate & Lyle
18.45
-5.68
-23.54%
CPB
Campbell Soup
20.88
-13.90
-39.96%
CAG
Conagra Brands
15.49
-7.75
-33.35%
PPC
Pilgrim's Pride
35.60
-11.32
-24.13%
INGR
Ingredion
113.33
-6.56
-5.47%
LW
Lamb Weston Holdings
40.58
-10.46
-20.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.